Показания к применению
Умеренная и тяжелая форма язвенного колита и болезнь Крона
Действующее вещество:
VEDOLIZUMAB
Описание препарата на английском
Ulcerative Colitis:Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF?) antagonist.Crohn’s Disease:Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNF?) antagonist.
| Характеристики | |
| По рецепту | по рецепту |
| Срок годности | 36 мес. |
| Форма употребления | POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION |
Ссылка на сайт МинЗдрава Израиля: http://www.old.health.gov.il/units/pharmacy/trufot/PerutTrufa.asp?Reg_Number=153 58 34277 00&safa=e
Ведолизумаб, Энтивио, Альдоксорубицин, Ксофиго, Лаферон-фармбиотек, Реальдирон, Экофемин цистоваг,